Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China
PLoS ONE2024Vol. 19(5), pp. e0302961–e0302961
Citations Over Time
Chaoneng He, Xiufang Mi, Gaoqi Xu, Xinglu Xu, Wenxiu Xin, Like Zhong, Junfeng Zhu, Qi Shu, Luo Fang, Haiying Ding
Abstract
Tislelizumab plus chemotherapy was probably cost-effective compared with chemotherapy alone as the first-line treatment for advanced or metastatic OSCC in China.
Related Papers
- → Rotator cuff repair: An analysis of utility scores and cost-effectiveness(2007)255 cited
- → The Decision Rules of Cost-Effectiveness Analysis(1996)205 cited
- → Cost-Effectiveness of Computer-Tailored Smoking Cessation Advice in Primary Care: A Randomized Trial (ESCAPE)(2013)20 cited
- → Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea(2017)7 cited
- → Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC)(2018)1 cited